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ABSTRACT 
Weijer, K., UytdeHaag, F.G.C.M. and Osterhaus, A.D.M.E., 1989. Control of feline leukaemia 
virus. Vet. Immunol. Immunopathol., 21: 69-83. 
Feline leukaemia virus (FeLV) usually occurs in its natural species, the domestic at. FeLV is 
also important to human individuals as a comparative model, as it may cause a variety of diseases, 
some malignant and some benign, such as immunosuppression, which bears a resemblance to 
AIDS (acquired immune deficiency syndrome) in man. 
FeLV is transmitted among cats by contagion. The main sources of infection are persistently 
infected carrier cats which continuously excrete virus. Dissemination of FeLV among cats may be 
prevented by identifying infected carrier cats and removing them from contact with non-infected 
cats. Removal programmes using indirect immunofluorescence antibody tests were applied suc- 
cessfully in The Netherlands. The proportion of FeLV-positive cats decreased from 9% in 1974 to 
approximately 3% in 1985 during such a programme. The results of a removal programme carried 
out in a catbreeders' ociety were even better: the incidence of cats positive for FeLV decreased 
from 11% in 1974 to less than 2% within 4 years. None of the cats tested in this society has been 
found to be positive for FeLV since 1984. 
Besides removal programmes, other methods of control, such as pre-exposure treatment, were 
developed to prevent he spread of FeLV. We attempted to protect kittens against oronasal infec- 
tion with FeLV by treatment with virus-neutralizing (VN) monoclonal antibodies (MoAbs) di- 
rected against an epitope on the viral glycoprotein gp70. However, no protection was achieved. It 
is unlikely that the amount of VN antibodies, the mode and route of their application or the 
infectious dose of FeLV used can account for this failure. Other possible xplanations for the lack 
of protective ffect are that (i) the restricted epitope specificity of the MoAb preparation used 
may have led to selection of neutralization-resistant virus mutants, or (ii) other mechanisms than 
virus neutralization (complement-mediated lysis, antibody-dependent cellcytotoxicity), that may 
be involved in protection, function less efficiently with MoAb. However, in the light of our finding 
that an early anti-idiotypic response is observed in all cats following administration of the MoAb 
preparation, the rapid clearance of anti-FeLV MoAb from the circulation is a more likely 
explanation. 
Efforts were further made to develop a vaccine for controlling FeLV infection. The immuno- 
stimulating complex vaccine (FeLV-ISCOM vaccine), a subunit vaccine in which FeLV gp70 is 
presented in a particular manner, looks promising. The protective ffect of FeLV-ISCOM vaccine 
was studied by vaccinating six 8-week-old SPF cats with ISCOM, followed by oronasal challenge 
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with FeLV. Six unvaccinated cats were also challenged with the same dose of FeLV. The vacci- 
nated cats developed FeLV serum antibodies, ome of which were directed to the shared epitope 
on gp70. At 10 weeks after challenge, none was viraemic, whereas four of the control cats had 
developed FeLV viraemia. The potential of FeLV-ISCOM vaccine to induce protective immunity 
in cats against FeLV was also shown in a field experiment. 
The generation ofan anti-idiotype vaccine was another approach to developing a FeLV vaccine. 
Virus-neutralizing mouse monoclonal ntibodies were generated against an epitope of FeLV gp70. 
Against one of these, MoAb 3 - 17, a panel of 15 anti-idiotype monoclonal ntibodies (MoAb2) was 
generated. They recognized partially overlapping private idiotypes within the paratope of MoAb 
3-17. Repeated immunization with these MoAb2 coupled to keyhole limpet haemocyanin (KLH) 
resulted in low-titered anti-FeLV serum titers in BALB/c mice. 
In a second series of experiments, rabbits were immunized with an affinity-purified polyclonal 
cat anti-FeLV neutralizing antibody preparation. Immunization ofBALB/c mice with Ig from 
these rabbits resulted in high anti-FeLV antibody titers within 3 weeks. 
INTRODUCTION 
Feline leukaemia virus (FeLV),  identif ied by Jar ret t  et al. (1964a,b) in 1964 
is an important  pathogen in cats and is probably the major nontraumat ic  cause 
of death in adult animals ( Jarrett ,  1985). The  virus is widely distr ibuted in cat 
populations, also in The  Nether lands (Weijer and Daams, 1976), and causes 
a variety of diseases including haemopoiet ic tumours ( lymphosarcoma/ leu-  
kaemia) ,  non-mal ignant  haemopoiet ic  diseases ( immunosuppression and 
anaemia)  and reproductive diseases ( infert i l i ty and abort ion) .  Because of the 
anti-prol i ferative syndromes uch as aplastic anaemia and fatal immunodefi -  
ciency disease, FeLV provides an important  paradigm for human AIDS, in- 
duced by the human immunodef ic iency virus (HIV)  (Wong-Staal  and Gallo, 
1985; Overbaugh et al., 1988). The control of virus diseases till depends largely 
on epidemiologic measures, including the appl ication of vaccinat ion strategies. 
Apart from pre-exposure immunoprophylaxis ,  there is also a serious need for 
specific post-exposure t reatment.  In the present paper we give an overview of 
these subjects, supplemented with recent data derived from our research iN 
this field. 
EPIDEMIOLOGIC MEASURES 
It was found by Hardy et al. (1973) and Jar ret t  et al. (1973) that  FeLV is 
t ransmit ted contagiously among cats. The  main source of infection is the per- 
sistently infected FeLV carr ier-cat which excretes virus cont inuously from the 
mouth and in other secretions ( Jarret t  et al., 1973; Francis et ah, 1977). 
Although much infectious virus may be present in the saliva, direct contact  
is usually required for the transmission of the virus. This  explains why the 
incidence of FeLV-related diseases is higher in cats kept in closed mult icat 
households than in free-range cats. Consequently,  FeLV-related diseases are 
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more frequently diagnosed in pedigree cats which are usually maintained in 
larger groups. 
Since control programmes aim at consistently destroying persistently vi- 
raemic cats, methods of diagnosing FeLV infection must be accurate. Until 
recently, the two methods most widely used to routinely diagnose FeLV-infec- 
tion were virus isolation from plasma samples (Jarrett et al., 1968) and im- 
munofluorescence arried out on blood smears (Hardy et al., 1973). These 
tests have been shown to give comparable results (Jarrett et al., 1982a). Re- 
cently, a third method which detects FeL¥ p27 antigen, has become available. 
This is an enzyme-linked immunosorbent assay (ELISA) that can be per- 
formed directly by veterinary surgeons. 
The spread of FeLV among cats can be prevented by detecting infected car- 
rier cats and removing them from contact with uninfected cats. Removal pro- 
grammes based on seropositivity in indirect immunofluorescence antibody 
(IFA) tests on air-dried blood smears have been used successfully in veterinary 
medicine for the past 12 years (Hardy et al., 1976; Weijer and Daams, 1978; 
Weijer et al., 1986a). Hardy et al. (1976) showed that when FeLV carrier cats 
were removed from non-infected animals, these households became free from 
FeL¥ infection, in contrast o similar multicat households where no such re- 
moval programme was implemented. This demonstrated for the first time that 
it was possible to prevent he contagious spread of a mammalian oncornavirus 
in the natural environment. 
In a similar European study, we showed that essentially the same results 
were obtained in a removal programme (Weijer et al., 1986a). In the period 
1974-1986, 47 070 blood smears from Dutch cats were examined by IFA. About 
20% of the blood smears came from cats suspected of FeLV-related disease. 
The remaining 80% came from cats participating in the removal programme. 
The results of this removal programme are depicted in Fig. 1. There was a 
decrease in the percentage of FeLV-positive cats from about 9% in 1974 to 
about 3% in 1986. 
In the same period the removal programme was carried out among cats be- 
longing to members of the Dutch cat breeders' society "Felikat", in which the 
programme was imposed on all the members. The results of this programme, 
in which more than 8000 blood smears were tested, are depicted in Fig. 2. The 
incidence of FeL¥-positive cats decreased from over 11% in 1974 to less than 
2% within 4 years. Since 1984 none of the cats tested within this society has 
proved to be FeLV-positive. Taken together, these data strongly suggest that 
the percentage of FeLV-carrier cats in a cat population can be reduced dra- 
matically by a removal programme in which FeLV-positive cats are traced by 
IFA, carried out on blood smears, and by subsequent prevention of further 
contacts of negative cats with these positive animals. From these results it can 
also be deduced that the conclusion of Pacitti (1987), that latently infected 
cats do not play a major role in maintaining the infection in cat populations, 
is probably correct. 
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Fig. 1. FeLV status of Dutch cats during a removal programme. 
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Fig. 2. FeLV status of cats in a large Dutch catbreeders' society (Felikat) during a removal 
programme. 
POST-EXPOSURE TREATMENT IN A RETROVIRUS SYSTEM 
In the absence of an effective and safe vaccine against certain retrovirus 
infections of mammals, including HIV in man, there is an urgent need for 
specific post-exposure treatment. Polyclonal xenogeneic or allogeneic antibod- 
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ies to FeLV gp70 with neutralizing activity are protective in cats when admin- 
istered through the colostrum (Hoover et al., 1977), or by systemic inocula- 
tion, provided that administration occurs within 6 days of exposure (De 
Noronha et al., 1977; Cotter et al., 1980; Haley et al., 1985). 
Because protection from viraemia is believed to be mediated at least partly 
by virus-neutralizing (VN) antibody directed against he envelope glycopro- 
rein gp70 of FeLV (Russell and Jarrett, 1978 ), passive immunization with neu- 
tralizing monoclonal antibodies against FeLV of subgroups A, B and C would 
appear to be a promising approach for the protection of cats after FeLV 
infection. 
In our post-exposure treatment experiment, ten 9-week-old female cats, di- 
vided into five groups of two, were used. All cats were infected oronasally on 
day 0 with 106 focus-forming units (ffu) of FeLV-A/Glasgow-1. All cats were 
immunized i.m. with 1 ml/kg body weight of a mixture of MoAbs 3-17 and 6- 
15 (3 mg/ml Ig) every 2 days over a 20-day period. Treatment of the first two 
cats started on day 0, the day of virus infection, and that of the other groups 
on days 10, 20, 30 or 40 after virus infection. Blood samples were collected every 
10 days except during the application period of the MoAbs when samples were 
taken every 2 days. Serological tests were carried out essentially as described 
previously (Osterhaus et al., 1985; Weijer et al., 1986b). The results of the 
serology are summarized in Fig. 3. 
No protection against oronasal FeLV-A infection was achieved since nine 
out of ten cats developed persistent viraemia fter virus challenge (Fig. 3A). 
Previous tudies (Jarrett et al., 1982b) had shown that oronasal infection with 
this dose of virus in kittens of this age could be expected to result in viraemia 
in about 85% of the cats. Our results contrast sharply with those of similar 
post-exposure passive immunization experiments carried out with xenogeneic 
or allogeneic polyclonal neutralizing anti-FeLV antibodies, in which a protec- 
tive effect was observed (De Noronha et al., 1977; Hoover et al., 1977; Cotter 
et al., 1980; Haley et al., 1985). The amount of virus-neutralizing antibodies, 
the mode and moment of their application, and the infection dose of FeLV 
used, do not differ essentially from those used in the above studies and thus 
should not account for the observed iscrepancy. Various other explanations 
may, however, be proposed. 
First, the xenogeneic MoAbs may be rapidly cleared from the circulation 
through the generation of anti-mouse Ig antibodies. Fig. 3D shows that the 
appearance of anti-mouse Ig antibodies correlates with the disappearance of 
the MoAbs (Fig. 3C) used. This may have occurred in our studies, since the 
presence of aggregated IgG in the inoculated materials was not investigated. 
Rapid clearance of administered IgG has been reported in studies using MoAbs 
for treatment of human cancer patients and against rejection of allografts 
(Miller et al., 1982; Gratama et al., 1984). From these and other studies it is 
clear that, apart from the expected anti-isotypic and anti-allotypic response, a 
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Fig. 3. Serology of ten cats in the passive immunization experiment. 
A: Immunofluorescence test for the detection of FeLV p27 (bar, positive; no bar, negative). 
B: Whole-virus (FL74) ELISA for the detection of feline antibodies directed against FeLV, using 
an HRP-labelled rabbit anti-cat Ig preparation as conjugate (log10 titer: 0.5-4.5). 
C: Whole-virus (FL74) ELISA for the detection of MoAbs 3-17/6-15 (murine MoAbs directed 
against FeL¥ gp 70) using an HRP-labelled goat anti-mouse Ig preparation as conjugate (log~o 
titer: 0.5-4.5). 
D: ELISA for the detection of antibodies directed against mouse Ig determinants (log~o titer: 0.5- 
4.5). 
E: Cross-linking ELISA for the detection of feline anti-idiotypic antibodies (bar means titer higher 
than 0.5 log]o; no bar means titer lower than 0.5 log]o). 
Blood samples were taken on days 10, 20, 30, 40, 50, 61, 72, 80, 89, 150, 192 and 234. The serology 
of the samples taken during the application period of MoAbs is not included in this figure. (Open 
squares: time of sampling. ) 
vigorous anti-idiotypic response could also be responsible for this phenome- 
non. This anti-idiotypic reaction is probably the dominant aspect of the im- 
mune response to multiple infusions of murine MoAb (Shawler et al., 1985). 
We also found that, apart from an anti-mouse IgG1 activity in cats, an anti- 
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idiotypic response was present shortly after initiation of treatment (Fig. 3E). 
These data support our hypothesis that administration f MoAb elicits a more 
vigorous anti-idiotypic response than polyclonal antibody, due to the presen- 
tation of only a limited set of idiotopes (UytdeHaag and Osterhaus, 1985). 
This potential drawback, namely arapid clearance as a consequence of an anti- 
idiotypic response, may possibly be overcome by the use of predefined mixtures 
of MoAbs resulting in a more heterogeneous setof idiotypic determinants. 
A second explanation for the different results might be the restricted epitope 
specificity of the MoAb preparation used, which may have produced a neu- 
tralization-resistant mutant selection. This could be overcome by using panels 
of MoAbs directed against different epitopes of the viral glycoprotein. In this 
respect we have shown that at least wo virus-neutralization-inducing epitopes 
are present on the viral glycoprotein ofFeLV of subgroups A, B and C (Weijer 
et al., 1986b). 
A third explanation could be the (sub)class of antibody used in our experi- 
ment (subclass IgG1). At present it is not clear to what extent he results 
obtained in the FeLV system are influenced by phenomena related to effective 
functions of different mouse antibody classes in the cat. 
Finally, it is emphasized that the protection achieved with polyclonal anti- 
FeLV post-exposure treatment may not have been due solely to virus neutral- 
ization. This might in fact be less efficient in combination with MoAbs, but 
other mechanisms such as antibody-dependent cellular cytotoxicity, comple- 
ment-mediated lysis and macrophage enhancement may also have played a 
role (Tax et al., 1983). 
PREVENTIVE VACCINATION 
It seems a good strategy to develop a FeLV vaccine that induces virus-neu- 
tralizing (VN) antibodies directed against FeLV gp70 because these antibodies 
may protect cats from viraemia (Russell and Jarrett, 1978). However, conven- 
tional vaccines based upon (a) whole live-attenuated viruses or (b) inacti- 
vated viruses till present major problems (Norrby, 1983). 
The following approaches were considered for developing a FeLV vaccine. 
(a) Whole live-attenuated virus vaccine. Attenuated virus strains may reverse 
to virulence, may be too pathogenic for immune-deficient i dividuals, cannot 
be used in the presence of natural antibody and may be prevented from repli- 
cation by interference mechanisms. In the FeLV system, whole live-attenuated 
virus vaccines are capable of inducing VN antibodies (Jarrett et al., 1974), but 
in one study, one out of nine cats vaccinated with such a vaccine developed a 
FeLV-negative lymphosarcoma 6 years after vaccination (Hardy, 1981 ). Thus, 
live FeLV virus vaccines may be too dangerous touse, possibly due to the fact 
that the viral genome may be integrated in the host cell DNA. A more effective 
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live vaccine might perhaps be developed with the aid of genetic engineering. A 
part of FeLV, for example FeLV gp70, could be inserted into the genome of a 
vector such as vaccinia virus and this construct might hen be used as a vaccine. 
Apart from a humoral and cell-mediated immunity against he vector, immu- 
nity against FeLV gp70 is also induced and this may protect cats against FeLV 
infection. A disadvantage of this approach is the pathogenicity of the vector 
itself and its potential for spreading among non-vaccinated individuals. 
(b) Inactivated virus vaccine. Various approaches have been considered for the 
vaccination ofcats against FeLV infection with inactivated vaccines. However, 
most of these were not successful or proved only of limited value. Not only the 
use of these inactivated vaccines but also of subunit and synthetic peptide 
vaccines, which include only those components ofthe virus known to elicit the 
desired immune response, isgreatly hampered by the lack of adequate systems 
for their immunogenic presentation (Olsen et al., 1976, 1977; Pedersen et al., 
1978). Lewis et al. (1981) described a subunit vaccine containing FeLV gp70 
that elicited a certain degree of protection against FeLV-infection in the ab- 
sence of the induction of VN antibody. This subunit vaccine was the prototype 
vaccine of the now commercially available FeLV vaccine Leukocell R (Norden 
Laboratories; Sharpee t al., 1986). 
Recently we described the induction of a protective immune response in cats 
against feline leukaemia virus infection with a novel structure for the antigenic 
presentation of membrane proteins: the immunostimulating complex (IS- 
COM) (Morein et al., 1984). ISCOM containing the gp70/85 of FeLV not only 
induced virus-neutralizing antibodies in cats, but also protection against in- 
fection after oronasal challenge with the virus (Osterhaus et al., 1985). No 
(VN) antibodies could be detected in the control cats. Results of this vacci- 
nation experiment are summarized in Table 1. After challenge, four out of six 
control cats became viraemic, while all vaccinated cats were protected against 
FeLV infection. That only four of six cats became viraemic during the course 
of the experiment is in accordance with what was to be expected on the basis 
of the challenge dose used and the age of the kittens at the day of challenge 
(Hoover et al., 1976; Jarrett et al., 1982b). 
To assess the potential of the commercial feline leukaemia virus vaccine 
Leukocell Rand a candidate subunit ISCOM FeLV vaccine (Osterhaus et al., 
1985) for inducing protective immunity in cats against FeLV infection under 
field conditions, we conducted a comparative trial in three groups of privately 
owned cats, kept under conventional conditions in single or multiple cat house- 
holds (Osterhaus et al., 1987a). Two groups of animals were vaccinated three 
times either with Leukocell Ror with the candidate ISCOM vaccine, both con- 
taining about the same amount of FeLV envelope glycoprotein (gp70). The 
third group was inoculated at the same intervals with a control preparation 
not containing FeLV antigen. Serological responses were measured with an 
TABLE 1 
Detection of viraemia and serologic response of cats vaccinated with FeLV/F422 ISCOM 
77 
Day0 Day 21 Day 35 Day 43 Day Day Day Day 
61 75 111 113 
E a CE  ~' VN ~' E CE  VN E CE  VN E CE  VN V d V V V 
AV 1.5 14 - 3.5 44 + 3.5 43 + 
2 1.5 - 3.5 32 3.5 23 - 
3 1 - 3.5 24 3.5 17 + 
4 1.5 8 - 4 19 3.5 25 - 
5 2 9 - 3.5 38 + 4 26 + 
6 - - 3 24 + 3.5 17 + 
B1 f _ _ _ 
4 . . . .  
5 - ND g - - 
+ + 
+ + + 
+ + + 
- + 
aE=EL ISA ( log 10); ( -=  < 1). 
~'CE = anti-gp/70/85 competition ELISA (%) ;  less than 5% reduction was considered negative. 
"VN -- virus neutralization; less than 2 was considered negative. 
dv  = v i raemia  ( + = IF, and Leukassay-F-positive ). 
~'A1-6 = vaccinated cats. 
fB 1 -6  = unvaccinated cats. 
~ND = not done. 
enzyme-linked immunosorbent assay, a membrane immunofluorescence t st 
(MIF) and in a virus-neutralization test, described earlier by Weijer et al. 
(1986b), before (day 0) and after vaccination (day 100). 
From our vaccination experiments we learned that a FeLV ISCOM candi- 
date vaccine prepared from conventionally produced FeLV, containing 3/2g of 
gp70/85 in a three-dose regimen, protects cats against FeLV infection and is 
highly effective in inducing anti-FeLV antibodies in cats under field condi- 
tions. The antibody response as measured in ELISA, MIF, VN (Fig. 4) and 
western blotting assays, proved superior to the commercially available conven- 
tionally adjuvanted inactivated whole virus vaccine Leukocell R. A pronounced 
booster effect was further seen in the respective assays of cats seropositive at 
day 0 in ELISA. Therefore ISCOM preparations might be especially valuable 
in studies such as recently proposed by Gibbs et al. (1988) and Levine et al. 
( 1988 ). In these, an inactivated conventionally adjuvanted HIV vaccine would 
be used to boost the specific immune response in clinically healthy seroposi- 
tives with the aim of gaining additional protection against the development of 
clinical symptoms of HIV infection. Although such experiments under field 
conditions cannot prove that extra protection is induced by immunization, the 
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Fig. 4. Antibody titer rise measured in virus neutralization tests. 
A: LeukocellR; B: ISCOM; C: control. 
serological data indicate that this is highly likely for the majority of ISCOM- 
vaccinated cats since the presence of VN antibody, even at very low titers, will 
apparently protect he cat from natural infection (Russell and Jarrett, 1978). 
Even if VN antibody fails to develop, some protective effect results (Osterhaus 
et al., 1985) so that other explanations for this protection should also be 
considered. 
All these data thus suggest that the ISCOM method of antigenic presenta- 
tion could be of great value in the construction of safe and effective nucleic- 
acid-free retrovirus vaccines, and justify efforts towards the development of a 
candidate ISCOM retrovirus vaccine. 
ANTI- IDIOTYPIC ANTIBODIES AS IMMUNOGENS 
Recent studies using the network concept of the immune system initially 
proposed by Jerne (1974), indicate that elements of the immune system itself, 
e.g. anti-idiotype (anti-id) antibodies, can replace "external" antigens in vac- 
cination. The basis of this concept is the mutual recognition of variable (V) 
domains of the elements of the immune system which form a continually com- 
municating web of idiotypes and anti-idiotypes. The amino acid sequence in 
the V region of an immunoglobulin determines the three-dimensional config- 
uration of its antigen-containing site and permits it to react with a certain 
epitope on a particular antigen or with a certain idiotope located within a par- 
ticular idiotype. An antibody (Ab 1 ) response upon injection with an antigen 
or an antibody (Abl) itself results in an anti-Id (Ab2) response recognizing 
idiotypes of the Abl. This in turn will elicit an Ab3 response regulating the 
Ab2 response by recognizing its idiotype specificities, ince an Ab2 may react 
with the antigen-binding site within the V region of Abl on the basis of a 
structural complement and represent a three-dimensional internal image of 
the epitope on the external antigen. Consequently, the administration f Ab2 
can trigger the immune system into expanding a population of Ab3-producing 
cells that not only bind to Ab2 but also to antigen. Ab2 can therefore probably 
replace antigen for vaccination purposes. 
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In the following pages we will review our data (UytdeHaag et al., 1986; Os- 
terhaus et al., 1987b; Weijer et al., 1988) which clearly show that anti-idiotypic 
antibodies (Ab2) in the feline leukaemia virus system are indeed capable of 
inducing antiviral immunity. They also indicate that this capacity is not re- 
stricted to Ab2 displaying the properties of true internal images. Various strat- 
egies using xenogeneic or allogeneic polyclonal and monoclonal Ab2 were 
explored. 
To generate an anti-Id vaccine, a panel of mouse monoclonal antibodies 
(Abl) was prepared against FeLV gp70 as described previously (Weijer et al., 
1986b). For the production of panel of MoAb2, BALB/c mice were immunized 
with MoAbl as described earlier (Osterhaus et al., 1988). Fifteen stable MoAb2- 
producing hybridomas were obtained. After inhibition experiments, we con- 
cluded that all MoAb2 were directed against private idiotypes of MoAbl. In 
competition studies it was shown that these MoAb2 recognized two different, 
partially overlapping idiotopes in the paratope of MoAbl, 3-17 (Table 2). 
Ab2(~ with specificity for either interstrain, recurrent or private idiotopes, 
have been shown capable of eliciting the synthesis of Ab3 responses with pre- 
defined Abl-like antigen specificity, even across allotype linkage or species 
barriers (for review see UytdeHaag et al., 1986). Using a selection of these 
MoAb2 in several immunization protocols, we therefore tried to induce activity 
of Ab3 sharing MoAbl, 3-17 anti-FeLV in BALB/c mice. In an initial experi- 
ment, 1 out of 20 mice immunized with 10 ttg of MoAb2 developed a low level 
of anti-FeLV antibody in an ELISA. This indicates that silent idiotypes of 
predefined antigen specificity may, in the absence of antigen, be induced by 
Ab2 defining a private paratope-related idiotope on MoAbl. Encouraged by 
the work of Legrain et al. (1985) and Sanchez and Legrain (1985), in which 
Ab3 were induced by sequential immunization with two different Ab2, we 
started a second series of experiments. In these, seven groups of five mice were 
immunized four times at 14-day intervals either with 50 ttg of the same KLH- 
TABLE 2 
Characteristics of MoAb2 
MoAb2 Specificity Inhibition of binding 
of MoAb2, 2-17-HRP 
to MoAbl, 3-17 
Group I 2-17 1A, 21A, Private Partial or 
1C 8B, 12B, and complete 
14B 15C 19B, paratope-related 
Group II 1B, 2A, 4B, Private and None 
5A, 6A, 6B. paratope-related 
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coupled MoAb2's (groups 1-6) or with different KLH-coupled MoAb2's di- 
rected against he various idiotypes of MoAbl each time (group 7). Twelve 
weeks after the final immunization, 10 out of 35 mice, randomly distributed 
over the groups 1-7, showed anti-FeLV serum antibodies in whole virus ELISA. 
In an attempt to induce antiviral immunity with polyclonal antibodies in a 
xenogeneic system, two rabbits were immunized four times with 100 yg Ig of 
an affinity-purified polyclonal cat anti-FeLV neutralizing antibody (Abl) that 
had been purified by protein-A Sepharose chromatography (Weijer et al., 1988). 
After these immunizations both rabbits exhibited astrong Ab2 response. 
Twelve BALB/c mice were immunized three times (days 0, 14, 150) with 
100 gg Ig, purified by protein-A Sepharose chromatography from the rabbit 
sera. Three weeks after the last immunization, 11 out of the 12 mice showed 
anti-FeLV serum antibody titers in an ELISA, while five of them also showed 
antibody in MIF. These results are summarized in Table 3. 
Although the immune responses elicited by Ab2 were inferior to those ob- 
tained with the subunit ISCOM vaccine, one should realise that in most virus 
systems only Ab2 preparations were used that are specific for one idiotype 
determinant on an Abl, with specificity for only one antigenic determinant of 
the virus. In several virus systems Ab2 was able to elicit virus-neutralizing 
antibody responses and T-cell-mediated responses (CTL and DTH) in the 
absence of antigen that seemed less MHC-restricted than those generated by 
antigens presented in the conventional way (for review see Osterhaus et al., 
1988). The use of Ab2 preparations may also prove valuable in situations of 
TABLE3 
Induct ion  of ant i -FeLV ant ibod ies  in BALB/c  mice  w i th  rabb i t  Ab2  
Mouse  Ab2 a EL ISA  t i te r  I' M IF  t i te r  ~' 
No.  
d0  d 17 d 28 d 170 d 0 d 170 
359 Ra6 IgG - -  10 30 300 - -  - -  
360 Ra6 IgG - -  100 100 1000 - -  - -  
361 Ra6 IgG-KLH - -  30 30 100 - -  - -  
362 Ra6 IgG-KLH - -  10 30 30 - -  64 
363 Ra6 IgG-po l  - -  10 10 10 - -  16 
364 Ra6 IgG-po l  - -  10 10 30 - -  8 
365 Ra7 IgG - -  30 100 3000 - -  8 
366 Ra7 IgG - -  10 30 1000 - -  - -  
367 Ra7 IgG-KLH - -  10 10 30 - -  - -  
368 Ra7 IgG-KLH - -  30 100 3000 - -  - -  
369 Ra7 IgG-po l  - -  10 10 30 - -  - -  
370 Ra7 IgG-po l  - -  - -  10 100 - -  32 
~'3 X 100 fig, subcutaneous ly ,  2nd  immunizat ion  d 14, 3rd  immunizat ion  d 150. 
~'Sera bsorbed  w i th  FEA-0  cells (0.5 X 106 cells//~l ) and  w i th  poo led  cat  sera  1:1, 30 rain,  37 ° C. 
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immune incompetence, when an individual is not able to respond adequately 
to a certain pathogen (Finberg and Ertl, 1986). In the future it may be possible 
to exploit the use of Ab2 to prevent certain undesirable (auto) immune reac- 
tions or to turn off unwanted effects of vaccines or virus infections. 
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